Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK/PD and Safety of Evogliptin in Hemodialysis Patients
NCT04195919Phase 1Completed
- Sponsor
- Dong-A ST
- Start
- Jul 2020
- Primary completion
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of DA5221-B2 in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Dong-A ST. Primary endpoints: Area Under the Concentration-Time Curve from Time Zero to Last Quantifiable Concentration at 48 hours and Maximum Plasma Concentration at 48 hours. Started Jul 2020; status: completed.
02
Drugs
DA5221-B2
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT04195919.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04195919.